BioCentury
ARTICLE | Clinical News

ASM8: Phase IIa data

May 14, 2012 7:00 AM UTC

The double-blind, 3-way crossover, Canadian Phase IIa TPI ASM8-207 trial in 16 patients with allergic asthma showed that once-daily 3 and 7.8 mg inhaled ASM8 administered via a nebulizer significantly...